{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:53:05Z","timestamp":1791265985182,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Symbiosis International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05554-4","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:24:05Z","timestamp":1783873445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-specific membrane antigen based diagnostic and therapeutic integration for prostate cancer management"],"prefix":"10.1007","volume":"17","author":[{"given":"Tanu","family":"Dixit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Sawardekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sreeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvan","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"issue":"4","key":"5554_CR1","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1007\/s10967-026-10852-w","volume":"335","author":"TP Varghese","year":"2026","unstructured":"Varghese TP, Vijayan A, MPC N, Vijayakumar PR. The role of radiopharmaceuticals in biomedical science and clinical practice: from diagnostic imaging to targeted therapy. J Radioanal Nucl Chem. 2026;335(4):3331\u201341.","journal-title":"J Radioanal Nucl Chem"},{"issue":"31","key":"5554_CR2","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.2174\/1381612826666200605121054","volume":"26","author":"E Slonimsky","year":"2020","unstructured":"Slonimsky E, Tulchinsky M. Radiotheragnostics paradigm for radioactive iodine (Iodide) management of differentiated thyroid cancer. Curr Pharm Design. 2020;26(31):3812\u201327.","journal-title":"Curr Pharm Design"},{"key":"5554_CR3","unstructured":"M\u00e4\u00e4tt\u00e4 K, Uusiautti S. Radiopharmaceutical Therapy Speakers Abstracts."},{"issue":"6","key":"5554_CR4","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1148\/rg.2020200021","volume":"40","author":"JF Gomes Marin","year":"2020","unstructured":"Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, Buchpiguel CA. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. Radiographics. 2020;40(6):1715\u201340.","journal-title":"Radiographics"},{"key":"5554_CR5","doi-asserted-by":"crossref","unstructured":"Barca C, Griessinger CM, Faust A, Depke D, Essler M, Windhorst AD, Devoogdt N, Brindle KM, Sch\u00e4fers M, Zinnhardt B, Jacobs AH. 2021. Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy. Pharmaceuticals, 15(1), p.13.","DOI":"10.3390\/ph15010013"},{"issue":"15","key":"5554_CR6","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.3390\/ijms26157396","volume":"26","author":"RC Christodoulou","year":"2025","unstructured":"Christodoulou RC, Papageorgiou PS, Pitsillos R, Woodward A, Papageorgiou SG, Solomou EE, Georgiou MF. A Narrative Review of Theranostics in Neuro-Oncology: Advancing Brain Tumor Diagnosis and Treatment Through Nuclear Medicine and Artificial Intelligence. Int J Mol Sci. 2025;26(15):7396.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"5554_CR7","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers13163967","volume":"13","author":"M El Fakiri","year":"2021","unstructured":"El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC. PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives. Cancers. 2021;13(16):3967.","journal-title":"Cancers"},{"issue":"8","key":"5554_CR8","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.7150\/thno.92612","volume":"14","author":"M Sallam","year":"2024","unstructured":"Sallam M, Nguyen NT, Sainsbury F, Kimizuka N, Muyldermans S, Bene\u0161ov\u00e1-Sch\u00e4fer M. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future? Theranostics. 2024;14(8):3043.","journal-title":"Theranostics"},{"issue":"6","key":"5554_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.61882\/smmr.202501.06.05","volume":"1","author":"M Hasanzadeh","year":"2025","unstructured":"Hasanzadeh M, Tasharrofi MA, Ramezani S, Hariri S, Talebi Eilanlou A. Whole-Body PET\/CT Radioligand Imaging for Metastatic Disease Across Solid Tumors: Current Diagnostic Accuracy, Comparative Modalities, and Future Horizons. Stud Multidisciplinary Med Res. 2025;1(6):39\u201359.","journal-title":"Stud Multidisciplinary Med Res"},{"key":"5554_CR10","doi-asserted-by":"crossref","unstructured":"Strand SE, Altai M, Strand J, Ulmert D. Radionuclide-based Diagnosis and Therapy of Prostate Cancer. Handbook of Nuclear Medicine and Molecular Imaging for Physicists. CRC; 2022. pp. 255\u2013303.","DOI":"10.1201\/9780429489501-19"},{"issue":"6","key":"5554_CR11","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.7150\/thno.96675","volume":"14","author":"Y Song","year":"2024","unstructured":"Song Y, Zou J, Castellanos EA, Matsuura N, Ronald JA, Shuhendler A, Weber WA, Gilad AA, M\u00fcller C, Witney TH, Chen X. Theranostics-a sure cure for cancer after 100 years? Theranostics. 2024;14(6):2464.","journal-title":"Theranostics"},{"issue":"8","key":"5554_CR12","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/ph18081215","volume":"18","author":"W Jalloul","year":"2025","unstructured":"Jalloul W, Ghizdovat V, Saviuc A, Jalloul D, Grierosu IC, Stefanescu C. Targeted Alpha Therapy: Exploring the Clinical Insights into [225Ac] Ac-PSMA and Its Relevance Compared with [177Lu] Lu-PSMA in Advanced Prostate Cancer Management. Pharmaceuticals. 2025;18(8):1215.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"5554_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874471012666190729151540","volume":"13","author":"S Pastorino","year":"2020","unstructured":"Pastorino S, Riondato M, Uccelli L, Giovacchini G, Giovannini E, Duce V, Ciarmiello A. Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr radiopharmaceuticals. 2020;13(1):63\u201379.","journal-title":"Curr radiopharmaceuticals"},{"issue":"4","key":"5554_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2741\/4742","volume":"24","author":"B Vorlova","year":"2019","unstructured":"Vorlova B, Knedlik T, Tykvart J, Konvalinka J. GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond. Front Bioscience-Landmark. 2019;24(4):648\u201387.","journal-title":"Front Bioscience-Landmark"},{"issue":"21","key":"5554_CR15","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1111\/bph.13576","volume":"173","author":"JC Evans","year":"2016","unstructured":"Evans JC, Malhotra M, Cryan JF, O\u2019Driscoll CM. The therapeutic and diagnostic potential of the prostate specific membrane antigen\/glutamate carboxypeptidase II (PSMA\/GCPII) in cancer and neurological disease. Br J Pharmacol. 2016;173(21):3041\u201379.","journal-title":"Br J Pharmacol"},{"key":"5554_CR16","unstructured":"Pt\u00e1\u010dek J. (2018). Glutamate Carboxypeptidase II-Structural and Biochemical Characterization and Structure-Assisted Drug Design."},{"key":"5554_CR17","doi-asserted-by":"crossref","unstructured":"Sallam M, Nguyen NT, Sainsbury F, Kimizuka N, Muyldermans S, Bene\u0161ov\u00e1-Sch\u00e4fer M. 2024. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future? Theranostics, 14(8), p.3043.","DOI":"10.7150\/thno.92612"},{"issue":"5","key":"5554_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","volume":"45","author":"P Backhaus","year":"2018","unstructured":"Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, B\u00f6gemann M, Stegger L, Weckesser M, Schaefers M, Rahbar K. Targeting PSMA by radioligands in non-prostate disease\u2014current status and future perspectives. Eur J Nucl Med Mol Imaging. 2018;45(5):860\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"5554_CR19","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.3390\/cancers14164039","volume":"14","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Dall\u2019Armellina S, Pizzuto DA, Perotti G, Zagaria L, Lanni V, Treglia G, Racca M, Annunziata S. PSMA radioligand uptake as a biomarker of neoangiogenesis in solid tumours: diagnostic or theragnostic factor? Cancers. 2022;14(16):4039.","journal-title":"Cancers"},{"key":"5554_CR20","doi-asserted-by":"crossref","unstructured":"Currie GM, Rohren EM. Prostate cancer, part 2: PSMA and beyond. Journal of Nuclear Medicine Technology; 2026.","DOI":"10.2967\/jnmt.125.271979"},{"issue":"1","key":"5554_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Reviews Urol. 2025;22(1):26\u201345.","journal-title":"Nat Reviews Urol"},{"issue":"9","key":"5554_CR22","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1134\/S0006297920090011","volume":"85","author":"AA Rosenkranz","year":"2020","unstructured":"Rosenkranz AA, Slastnikova TA. Epidermal growth factor receptor: key to selective intracellular delivery. Biochem (Moscow). 2020;85(9):967\u201393.","journal-title":"Biochem (Moscow)"},{"issue":"2","key":"5554_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/biomedicines14020482","volume":"14","author":"X Ren","year":"2026","unstructured":"Ren X, Zhang L, An R, Song H, Shi M, Wang Z. Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer. Biomedicines. 2026;14(2):482.","journal-title":"Biomedicines"},{"issue":"5","key":"5554_CR24","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1097\/01.ju.0000091655.77601.0c","volume":"170","author":"NH Bander","year":"2003","unstructured":"Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170(5):1717\u201321.","journal-title":"J Urol"},{"key":"5554_CR25","doi-asserted-by":"crossref","unstructured":"Mishra A, Lisok A, Mease RC, Nov\u00e1kov\u00e1 Z, Gupta K, Sharma AK, Nimmagadda S. PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden\u2013Driven Variability. Journal of Nuclear Medicine; 2026.","DOI":"10.2967\/jnumed.125.271053"},{"key":"5554_CR26","doi-asserted-by":"publisher","first-page":"1455428","DOI":"10.3389\/fonc.2024.1455428","volume":"14","author":"A Lancia","year":"2024","unstructured":"Lancia A, Ingrosso G, Detti B, Festa E, Bonzano E, Linguanti F, Camilli F, Bertini N, La Mattina S, Orsatti C, Francolini G. Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope? Front Oncol. 2024;14:1455428.","journal-title":"Front Oncol"},{"issue":"4","key":"5554_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3892\/mmr.2026.13832","volume":"33","author":"R Watanabe","year":"2026","unstructured":"Watanabe R, Sakaue T, Miura N, Kikugawa T, Saika T. Prostate-specific membrane antigen: Molecular functions and emerging roles as a therapeutic target. Mol Med Rep. 2026;33(4):122.","journal-title":"Mol Med Rep"},{"issue":"6","key":"5554_CR28","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.bioconjchem.5b00679","volume":"27","author":"S Ray Banerjee","year":"2016","unstructured":"Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, Pomper MG. Preclinical comparative study of 68Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA. Bioconjug Chem. 2016;27(6):1447\u201355.","journal-title":"Bioconjug Chem"},{"issue":"8","key":"5554_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/ph14080713","volume":"14","author":"U Hennrich","year":"2021","unstructured":"Hennrich U, Eder M. [68Ga] Ga-PSMA-11: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals. 2021;14(8):713.","journal-title":"Pharmaceuticals"},{"key":"5554_CR30","doi-asserted-by":"crossref","unstructured":"Agarwal G, Sangwan K. (2026). FDA-Approved Radiopharmaceuticals in Oncologic PET Imaging: Current Status and Clinical Impact. Am J Clin Oncol, 10\u20131097.","DOI":"10.1097\/COC.0000000000001314"},{"issue":"2","key":"5554_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/jne7020033","volume":"7","author":"ML Terranova","year":"2026","unstructured":"Terranova ML. Redefining PET Imaging Through Nuclear Properties, Production Technologies and Scalability of Diagnostic Radionuclides. J Nuclear Eng. 2026;7(2):33.","journal-title":"J Nuclear Eng"},{"key":"5554_CR32","doi-asserted-by":"crossref","unstructured":"Avilez, N. D., Tineo, R. N., Rodrigues, J. T., Ottaiano, A. D., Saito, H. P., Amorim,B. J., \u2026 Ramos, C. D. (2026). Comparison of [18F] FDG and [18F] PSMA-1007 PET\/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study. Molecular Imaging and Biology, 1\u201311.","DOI":"10.1007\/s11307-026-02085-w"},{"key":"5554_CR33","doi-asserted-by":"crossref","unstructured":"Kessel K, Bernemann C, B\u00f6gemann M, Rahbar K. 2021. Evolving castration resistance and prostate specific membrane antigen expression: implications for patient management. Cancers, 13(14), p.3556.","DOI":"10.3390\/cancers13143556"},{"key":"5554_CR34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"O Sartor","year":"2024","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 versus ARPI change in mCRPC (PSMAfore): Phase III randomised trial. Lancet. 2024;404:1227\u201339.","journal-title":"Lancet"},{"issue":"17","key":"5554_CR35","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.3390\/cancers14174276","volume":"14","author":"EE Parent","year":"2022","unstructured":"Parent EE, Kase AM. A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancer. Cancers. 2022;14(17):4276.","journal-title":"Cancers"},{"issue":"17","key":"5554_CR36","doi-asserted-by":"publisher","first-page":"9755","DOI":"10.3390\/ijms25179755","volume":"25","author":"J Maes","year":"2024","unstructured":"Maes J, Gesquiere S, De Spiegeleer A, Maes A, Van de Wiele C. Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy. Int J Mol Sci. 2024;25(17):9755.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5554_CR37","doi-asserted-by":"publisher","first-page":"728","DOI":"10.3390\/pharmaceutics14040728","volume":"14","author":"H Cho","year":"2022","unstructured":"Cho H, Jeon SI, Ahn CH, Shim MK, Kim K. Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation. Pharmaceutics. 2022;14(4):728.","journal-title":"Pharmaceutics"},{"issue":"1","key":"5554_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","volume":"47","author":"S Vaz","year":"2020","unstructured":"Vaz S, Hadaschik B, Gabriel M, Herrmann K, Eiber M, Costa D. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(1):9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"5554_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","volume":"43","author":"MT Freitag","year":"2016","unstructured":"Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A. Comparison of hybrid 68Ga-PSMA PET\/MRI and 68Ga-PSMA PET\/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):70\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"5554_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36922\/ARNM025040005","volume":"3","author":"A Jain","year":"2025","unstructured":"Jain A, Kheruka S, Usmani S, Al Riyami K, Al Busaidi A, Bichpuria S, Sukaiti A, R. Exploring tumor heterogeneity: The role of PET\/CT with various radiopharmaceuticals in diagnosis and treatment guidance. Adv Radiotherapy Nuclear Med. 2025;3(2):1\u201315.","journal-title":"Adv Radiotherapy Nuclear Med"},{"key":"5554_CR41","doi-asserted-by":"crossref","unstructured":"Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. 2018. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. bmj, 362.","DOI":"10.1136\/bmj.k3519"},{"issue":"11","key":"5554_CR42","first-page":"1466","volume":"44","author":"LIU Xin","year":"2015","unstructured":"Xin LIU, Jie TANG, Xiang FEI, Qiu-Yang LI. Prostate-specific antigen (PSA) density and free to total PSA ratio in diagnosing prostate cancer with prostate-specific antigen levels of 4.0 ng\/ml or less. Iran J Public Health. 2015;44(11):1466.","journal-title":"Iran J Public Health"},{"key":"5554_CR43","doi-asserted-by":"crossref","unstructured":"Holzgreve, A., Armstrong, W. R., Clark, K. J., Benz, M. R., Smith, C. P., Djaileb,L., \u2026 Calais, J. (2025). PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Network Open, 8(1), e2452971.","DOI":"10.1001\/jamanetworkopen.2024.52971"},{"issue":"1","key":"5554_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1148\/rg.2019180079","volume":"39","author":"FG Barbosa","year":"2019","unstructured":"Barbosa FG, Queiroz MA, Nunes RF, Viana PC, Marin JFG, Cerri GG, Buchpiguel CA. Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread. Radiographics. 2019;39(1):186\u2013212.","journal-title":"Radiographics"},{"key":"5554_CR45","doi-asserted-by":"publisher","first-page":"1216894","DOI":"10.3389\/fonc.2023.1216894","volume":"13","author":"R Huang","year":"2023","unstructured":"Huang R, Li Y, Wu H, Liu B, Zhang X, Zhang Z. 68Ga-PSMA-11 PET\/CT versus 68Ga-PSMA-11 PET\/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1216894.","journal-title":"Front Oncol"},{"key":"5554_CR46","doi-asserted-by":"crossref","unstructured":"Fanti, S., Goffin, K., Hadaschik, B. A., Herrmann, K., Maurer, T., MacLennan, S.,\u2026 Bjartell, A. (2021). Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. European journal of nuclear medicine and molecular imaging, 48(2),469\u2013476.","DOI":"10.1007\/s00259-020-04934-4"},{"issue":"4","key":"5554_CR47","first-page":"355","volume":"88","author":"H Dadgar","year":"2021","unstructured":"Dadgar H, Seyedi Vafaee M, Norouzbeigi N, Jafari E, Gholamrezanezhad A, Assadi M. Dual-phase 68Ga-PSMA-11 PET\/CT may increase the rate of detected lesions in prostate cancer patients. Urol J. 2021;88(4):355\u201361.","journal-title":"Urol J"},{"issue":"11","key":"5554_CR48","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"E Demirci","year":"2016","unstructured":"Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun. 2016;37(11):1169\u201379.","journal-title":"Nucl Med Commun"},{"key":"5554_CR49","doi-asserted-by":"crossref","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, Costa LB, Zaniboni EC, Marin JFG, Cerri GG, Buchpiguel CA. 2020. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging, 20(1), p.23.","DOI":"10.1186\/s40644-020-00300-7"},{"key":"5554_CR50","doi-asserted-by":"crossref","unstructured":"Thakre S, Khan A, Ahmed R. (2025). Radiopharmaceuticals in Prostate Cancer Advancements in Early Detection and Targeted Therapy through PSMA-Based Imaging and Treatment Strategies.","DOI":"10.20944\/preprints202505.0108.v1"},{"issue":"4","key":"5554_CR51","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","volume":"49","author":"SM Peters","year":"2022","unstructured":"Peters SM, Hofferber R, Prive BM, de Bakker M, Gotthardt M, Janssen M, de Lange F, Muselaers CH, Mehra N, Witjes JA, Costa PF. [68Ga] Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu] Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2022;49(4):1101\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5554_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/MNM.0000000000001872","volume":"45","author":"AM Peters","year":"2024","unstructured":"Peters AM. The physiological basis of renal nuclear medicine. Nucl Med Commun. 2024;45(9):745\u201357.","journal-title":"Nucl Med Commun"},{"issue":"15","key":"5554_CR53","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3390\/molecules27154959","volume":"27","author":"J Lau","year":"2022","unstructured":"Lau J, Lee H, Rousseau J, B\u00e9nard F, Lin KS. Application of cleavable linkers to improve therapeutic index of radioligand therapies. Molecules. 2022;27(15):4959.","journal-title":"Molecules"},{"issue":"1","key":"5554_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","volume":"19","author":"BA Maiorano","year":"2024","unstructured":"Maiorano BA, De Giorgi U, Verzoni E, Maiello E, Procopio G, Conteduca V, Di Maio M, MeetURO group. Hematological toxicity of PARP inhibitors in metastatic prostate cancer patients with mutations of BRCA or HRR genes: a systematic review and safety meta-analysis. Target Oncol. 2024;19(1):1\u201311.","journal-title":"Target Oncol"},{"issue":"10","key":"5554_CR55","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.2967\/jnumed.119.240242","volume":"61","author":"A Gafita","year":"2020","unstructured":"Gafita A, Heck MM, Rauscher I, Tauber R, Cala L, Franz C, D\u2019Alessandria C, Retz M, Weber WA, Eiber M. Early prostate-specific antigen changes and clinical outcome after 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61(10):1476\u201383.","journal-title":"J Nucl Med"},{"key":"5554_CR56","doi-asserted-by":"crossref","unstructured":"Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Volume 15. Therapeutic Advances in Medical Oncology; 2023. p. 17588359231156392.","DOI":"10.1177\/17588359231156392"},{"issue":"10231","key":"5554_CR57","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"6","key":"5554_CR58","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.121.263638","volume":"63","author":"PH Kuo","year":"2022","unstructured":"Kuo PH, Benson T, Messmann R, Groaning M. Why we did what we did: PSMA PET\/CT selection criteria for the VISION trial. J Nucl Med. 2022;63(6):816\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"5554_CR59","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, K\u00fcrpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2017;58(2):312\u20139.","journal-title":"Soc Nuclear Med"},{"issue":"1","key":"5554_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41824-020-00085-9","volume":"4","author":"S Woo","year":"2020","unstructured":"Woo S, Ghafoor S, Becker AS, Han S, Wibmer AG, Hricak H, Burger IA, Sch\u00f6der H, Vargas HA. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J hybrid imaging. 2020;4(1):16.","journal-title":"Eur J hybrid imaging"},{"issue":"3","key":"5554_CR61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2967\/jnumed.117.202945","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM. Impact of 68Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med. 2018;59(3):434\u201341.","journal-title":"J Nucl Med"},{"issue":"4","key":"5554_CR62","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44(4):678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"5554_CR63","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2017;58(8):1196\u2013200.","journal-title":"Soc Nuclear Med"},{"issue":"3","key":"5554_CR64","first-page":"133","volume":"30","author":"H Lee","year":"2021","unstructured":"Lee H, Kim Y, Cho J. Relative efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in prostate cancer based on subcellular dosimetry. Mol Imaging Radionucl Therapy. 2021;30(3):133\u20139.","journal-title":"Mol Imaging Radionucl Therapy"},{"issue":"7","key":"5554_CR65","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","volume":"14","author":"AP Bidkar","year":"2024","unstructured":"Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14(7):2969.","journal-title":"Theranostics"},{"issue":"8","key":"5554_CR66","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.7150\/thno.106574","volume":"15","author":"G Ninatti","year":"2025","unstructured":"Ninatti G, et al. Time for action: Actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer\u2014a systematic review and meta-analysis. Theranostics. 2025;15(8):3386\u201399.","journal-title":"Theranostics"},{"issue":"8","key":"5554_CR67","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3390\/ph18081215","volume":"18","author":"W Jalloul","year":"2025","unstructured":"Jalloul W. Exploring the clinical insights into [225Ac] Ac-PSMA and its role in advanced prostate cancer. Pharmaceuticals. 2025;18(8):1215.","journal-title":"Pharmaceuticals"},{"key":"5554_CR68","unstructured":"Al-Ibraheem A, Moghrabi S, Abdlkadir AS. (2025). Evaluating xerostomia as a side effect of [225Ac] Ac-PSMA: A systematic review and meta-analysis. Eur J Clin Invest, 55(5), e14358."},{"key":"5554_CR69","doi-asserted-by":"crossref","unstructured":"Almeida, L. S., de Camargo Etchebehere, E. C. S., Meg\u00edas, I. G., Ter\u00e1n, A. K. C.,Hadaschik, B., Colletti, P. M., \u2026 Bolton, R. C. D. (2024). PSMA radioligand therapy in prostate cancer: where are we and where are we heading? Clinical Nuclear Medicine,49(1), 45\u201355.","DOI":"10.1097\/RLU.0000000000004919"},{"key":"5554_CR70","doi-asserted-by":"crossref","unstructured":"Vorster M, Sathekge M. July). Advances in PSMA alpha theragnostics. Seminars in Nuclear Medicine. Volume 54. WB Saunders; 2024. pp. 591\u2013602. 4.","DOI":"10.1053\/j.semnuclmed.2024.03.004"},{"issue":"4","key":"5554_CR71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3233\/HAB-200425","volume":"28","author":"RS Al-Baradie","year":"2020","unstructured":"Al-Baradie RS. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics. Hum Antib. 2020;28(4):259\u201372.","journal-title":"Hum Antib"},{"issue":"16","key":"5554_CR72","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3390\/cancers13164023","volume":"13","author":"H Zhang","year":"2021","unstructured":"Zhang H, Koumna S, Pouliot F, Beauregard JM, Kolinsky M. PSMA theranostics: current landscape and future outlook. Cancers. 2021;13(16):4023.","journal-title":"Cancers"},{"key":"5554_CR73","doi-asserted-by":"crossref","first-page":"1158496","DOI":"10.3389\/fonc.2023.1274264","volume":"13","author":"A Jang","year":"2023","unstructured":"Jang A, Pandey M, Kim J. The evolving role of PSMA-targeted radionuclide therapy in metastatic castration-resistant prostate cancer. Front Oncol. 2023;13:1158496.","journal-title":"Front Oncol"},{"key":"5554_CR74","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"O Sartor","year":"2024","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 versus ARPI change in mCRPC (PSMAfore): Phase III randomised trial. Lancet. 2024;404:1227\u201339.","journal-title":"Lancet"},{"issue":"11","key":"5554_CR75","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3390\/pharmaceutics14102166","volume":"14","author":"SW Ling","year":"2022","unstructured":"Ling SW, Rietbergen DDD, Bruchertseifer F, Morgenstern A, Brindle H. Targeted alpha therapy of prostate cancer using actinium-225-labeled PSMA ligands: From preclinical development to clinical application. Pharmaceutics. 2022;14(11):2166.","journal-title":"Pharmaceutics"},{"issue":"10","key":"5554_CR76","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","volume":"63","author":"M Hotta","year":"2022","unstructured":"Hotta M, Gafita A, Czernin J, Calais J. Outcome of patients with PSMA PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022;63(10):1484\u20138.","journal-title":"J Nucl Med"},{"key":"5554_CR77","doi-asserted-by":"crossref","unstructured":"Karimzadeh, A., Heck, M., Tauber, R., Solaris, E., Nekolla, S., Knorr, K., \u2026 Rauscher,I. (2023). The impact of PSMA PET\u2013based eligibility criteria used in the prospective phase II TheraP trial in metastatic castration-resistant prostate cancer patients undergoing prostate-specific membrane antigen\u2013targeted radioligand therapy. Journal of Nuclear Medicine, 64(8), 1252\u20131258.","DOI":"10.2967\/jnumed.122.265346"},{"issue":"5","key":"5554_CR78","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","volume":"28","author":"B Ramnaraign","year":"2023","unstructured":"Ramnaraign B, Sartor O. PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials. Oncologist. 2023;28(5):392\u2013401.","journal-title":"Oncologist"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05554-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05554-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:03:20Z","timestamp":1791263000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05554-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5554"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05554-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review article did not involve any animal subjects, human participants or confidential data. It is a review based on published literature. Hence, no ethical approval was required consent to participate is not applicable as no human participants were directly involved and no primary data was collected for this review article.","order":1,"name":"Ethics","label":"Ethics approval and consent to particiapte","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article does not contain any personal data or images related to individual participants. Hence consent for publication is not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1408"}}